A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma

被引:134
作者
Nowak, AK
Byrne, MJ
Williamson, R
Ryan, G
Segal, A
Fielding, D
Mitchell, P
Musk, AW
Robinson, BWS
机构
[1] Sir Charles Gairdner Hosp, Dept Med Oncol, Nedlands, WA 6009, Australia
[2] Sir Charles Gairdner Hosp, Dept Resp Med, Nedlands, WA 6009, Australia
[3] Univ Western Australia, Dept Med, Nedlands, WA 6009, Australia
[4] Univ Western Australia, Dept Publ Hlth, Nedlands, WA 6009, Australia
[5] Sir Charles Gairdner Hosp, Pathctr, Nedlands, WA 6009, Australia
[6] Princess Alexandra Hosp, Dept Resp Med, Brisbane, Qld 4102, Australia
[7] Austin & Repatriat Med Ctr, Dept Med Oncol, Melbourne, Vic, Australia
关键词
malignant mesothelioma; gemcitabine; cisplatin; quality of life; drug treatment;
D O I
10.1038/sj.bjc.6600505
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Our previous phase II study of cisplatin and gemcitabine in malignant mesothelioma showed a 47.6% (95% CI 26.2-69.0%) response rate with symptom improvement in responding patients. Here we confirm these findings in a multicentre setting, and assess the effect of this treatment on quality of life and pulmonary function. Fifty-three patients with pleural malignant mesothelioma received cisplatin 100 mg m(-2) i.v. day I and gemcitabine 1000 mg m-2 i.v. days 1, 8, and 15 of a 28 day cycle for a maximum of six cycles. Quality of life and pulmonary function were assessed at each cycle. The best response achieved in 52 assessable patients was: partial response, 17 (33%, 95% CI 20-46%); stable disease, 31 (60%); and progressive disease, four (8%). The median time to disease progression was 6.4 months, median survival from start of treatment 11.2 months, and median survival from diagnosis 17.3 months. Vital capacity and global quality of life remained stable in all patients and improved significantly in responding patients. Major toxicities were haematological, limiting the mean relative dose intensity of gemcitabine to 75%. This schedule of cisplatin and gemcitabine is active in malignant mesothelioma in a multicentre setting. Investigation of alternative scheduling is needed to decrease haematological toxicity and increase the relative dose intensity of gemcitabine whilst maintaining response rate and quality of life.
引用
收藏
页码:491 / 496
页数:6
相关论文
共 34 条
  • [1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY
    AARONSON, NK
    AHMEDZAI, S
    BERGMAN, B
    BULLINGER, M
    CULL, A
    DUEZ, NJ
    FILIBERTI, A
    FLECHTNER, H
    FLEISHMAN, SB
    DEHAES, JCJM
    KAASA, S
    KLEE, M
    OSOBA, D
    RAZAVI, D
    ROFE, PB
    SCHRAUB, S
    SNEEUW, K
    SULLIVAN, M
    TAKEDA, F
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) : 365 - 376
  • [2] Abratt RP, 1998, SEMIN ONCOL, V25, P35
  • [3] Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer
    Abratt, RP
    Bezwoda, WR
    Goedhals, L
    Hacking, DJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 744 - 749
  • [4] AISNER J, 1995, CHEST, V108, P1122
  • [5] [Anonymous], 1992, TNM classification of malignant tumors
  • [6] Bischoff HG, 1998, P AN M AM SOC CLIN, V17, P1784
  • [7] Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study
    Byrne, MJ
    Davidson, JA
    Musk, AW
    Dewar, J
    van Hazel, G
    Buck, M
    de Klerk, NH
    Robinson, BWS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 25 - 30
  • [8] Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study
    Crino, L
    Scagliotti, G
    Marangolo, M
    Figoli, F
    Clerici, M
    DeMarinis, F
    Salvati, F
    Cruciani, G
    Dogliotti, L
    Pucci, F
    Paccagnella, A
    Adamo, V
    Altavilla, G
    Incoronato, P
    Trippetti, M
    Mosconi, AM
    Santucci, A
    Sorbolini, S
    Oliva, C
    Tonato, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 297 - 303
  • [9] DEKLERK NH, 1989, MED J AUSTRALIA, V151, P616
  • [10] Combination raltitrexed (Tomudex®)-oxaliplatin:: a step forward in the struggle against mesothelioma?: The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
    Fizazi, K
    Caliandro, R
    Soulié, P
    Fandi, A
    Daniel, C
    Bedin, A
    Doubre, H
    Viala, J
    Rodier, JM
    Trandafir, L
    Le Chevalier, T
    Cvitkovic, E
    Armand, JP
    Ruffié, P
    [J]. EUROPEAN JOURNAL OF CANCER, 2000, 36 (12) : 1514 - 1521